Psyence Biomedical Ltd. (Nasdaq: PBM), also known as Psyence BioMed, is a biopharmaceutical and life sciences biotechnology company focused on nature-derived psilocybin and ibogaine-based psychedelic medicine. Its news flow reflects activity across clinical development, manufacturing, capital markets, and strategic partnerships.
Readers of the PBM news page can expect updates on the company’s Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in palliative care or in patients with cancer. News releases describe milestones such as patient dosing, expansion of clinical sites in Australia, and ethics approvals for the use of PsyLabs’ psilocybin product in the trial.
The company also issues announcements on its ibogaine operations and supply chain, including the establishment of sustainable iboga bark sourcing in Africa and the production of GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) and Total Alkaloid Extracts through its partner PsyLabs. These updates highlight progress in securing psychedelic active pharmaceutical ingredients for clinical and therapeutic markets.
Other PBM news items cover strategic investments and financial decisions, such as follow-on investments in PsyLabs, share consolidation (reverse stock split) actions, and capital management frameworks that include potential share repurchase programs, as described by the company. Communications may also address leadership changes, board appointments, and corporate governance developments disclosed in conjunction with SEC filings.
In addition, Psyence BioMed publishes news on its psilocybin longevity research initiative, which examines biological markers associated with aging, and on its broader positioning in the emerging psychedelics and longevity sectors. Investors and observers who follow PBM news can use this page to track the company’s clinical progress, manufacturing capabilities, and regulatory and capital markets updates over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.